Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
Public ClinicalTrials.gov record NCT00861744. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Observer Blind, Controlled, Multicenter Study to Assess Immunogenicity and Antibody Persistence Following Vaccination With GSK's Candidate Combined Measles, Mumps, and Rubella Vaccine (MMR) Versus M-M-R® II as a First Dose, Both Administered Subcutaneously at 12-15 Months of Age, Concomitantly With Hepatitis A Vaccine (HAV), Varicella Vaccine (VV) and Pneumococcal Conjugate Vaccine (PCV) But at Separate Sites.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first vaccination. Additionally, antibody persistence will be assessed one and two years after administration of MMR vaccine. The Protocol Posting has been updated following Protocol amendment 1 and 2, Oct 2009.
Study identification
- NCT ID
- NCT00861744
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 1,259 participants
Conditions and interventions
Conditions
Interventions
- GSK Biological's investigational vaccine 209762 Biological
- M-M-R® II (Merck and Co) Biological
- Varivax® Biological
- Havrix® Biological
- Prevnar® Biological
Biological
Eligibility (public fields only)
- Age range
- 12 Months to 15 Months
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 3, 2009 (Actual)
- Primary completion
- Jul 21, 2010 (Actual)
- Completion
- Jun 18, 2012 (Actual)
- Last update posted
- Jan 3, 2020
2009 – 2012
United States locations
- U.S. sites
- 45
- U.S. states
- 27
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Tuscaloosa | Alabama | 35401 | — |
| GSK Investigational Site | Conway | Arkansas | 72034 | — |
| GSK Investigational Site | Jonesboro | Arkansas | 72401 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72205 | — |
| GSK Investigational Site | Anaheim | California | 92804 | — |
| GSK Investigational Site | Downey | California | 90241 | — |
| GSK Investigational Site | Fresno | California | 93720 | — |
| GSK Investigational Site | Huntington Beach | California | 92647 | — |
| GSK Investigational Site | Paramount | California | 90723 | — |
| GSK Investigational Site | Santa Ana | California | 92701-4607 | — |
| GSK Investigational Site | West Covina | California | 91790 | — |
| GSK Investigational Site | Altamonte Springs | Florida | 32701 | — |
| GSK Investigational Site | Dalton | Georgia | 30721 | — |
| GSK Investigational Site | Marietta | Georgia | 30062 | — |
| GSK Investigational Site | Nampa | Idaho | 83686 | — |
| GSK Investigational Site | DeKalb | Illinois | 60115 | — |
| GSK Investigational Site | Arkansas City | Kansas | 67005 | — |
| GSK Investigational Site | Bardstown | Kentucky | 40004 | — |
| GSK Investigational Site | Bossier City | Louisiana | 71111 | — |
| GSK Investigational Site | Metairie | Louisiana | 70006 | — |
| GSK Investigational Site | Baltimore | Maryland | 21021 | — |
| GSK Investigational Site | Fall River | Massachusetts | 02724 | — |
| GSK Investigational Site | Kansas City | Missouri | 64108 | — |
| GSK Investigational Site | Great Falls | Montana | 59405 | — |
| GSK Investigational Site | Henderson | Nevada | 89015 | — |
| GSK Investigational Site | Utica | New York | 13502 | — |
| GSK Investigational Site | Cary | North Carolina | 27518 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27609 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45245 | — |
| GSK Investigational Site | Dayton | Ohio | 45406 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74127 | — |
| GSK Investigational Site | Gresham | Oregon | 97030 | — |
| GSK Investigational Site | East Norriton | Pennsylvania | 19401 | — |
| GSK Investigational Site | Rydal | Pennsylvania | 19046 | — |
| GSK Investigational Site | Charleston | South Carolina | 29406 | — |
| GSK Investigational Site | Bristol | Tennessee | 37620 | — |
| GSK Investigational Site | Kingsport | Tennessee | 37660 | — |
| GSK Investigational Site | Corpus Christi | Texas | 78411 | — |
| GSK Investigational Site | Layton | Utah | 84041 | — |
| GSK Investigational Site | Provo | Utah | 84604 | — |
| GSK Investigational Site | Springville | Utah | 84663 | — |
| GSK Investigational Site | St. George | Utah | 84790 | — |
| GSK Investigational Site | West Jordan | Utah | 84088 | — |
| GSK Investigational Site | Virginia Beach | Virginia | 23454 | — |
| GSK Investigational Site | Huntington | West Virginia | 25701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00861744, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 3, 2020 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00861744 live on ClinicalTrials.gov.